phrykt

Alnylam Pharmaceuticals (ALNY) net income: $314M

Alnylam Pharmaceuticals reported a net income of $314M for the year ended Dec 31, 2025.

From Alnylam Pharmaceuticals's filings with the SEC · Read the filing · ALNY stock page

Alnylam Pharmaceuticals net income by year

−$853M2021−$1.1B2022−$440M2023−$278M2024$314M2025

#784 of 3,748 US companies by net income · See the full ranking

Year endedNet incomeChange
Dec 31, 2025$314M–
Dec 31, 2024−$278M–
Dec 31, 2023−$440M–
Dec 31, 2022−$1.1B–
Dec 31, 2021−$853M–

Net income of similar companies

Companies in the same industry as Alnylam Pharmaceuticals, by SEC industry code, with the closest net income. Each name opens the same page for that company.

CompanyNet income, latest yearYear ended
Acadia Pharmaceuticals$391MDec 31, 2025
Rigel Pharmaceuticals$367MDec 31, 2025
Biomarin Pharmaceutical$349MDec 31, 2025
Alnylam Pharmaceuticals$314MDec 31, 2025
Aurinia Pharmaceuticals$287MDec 31, 2025
BeOne Medicines$287MDec 31, 2025
Alkermes$242MDec 31, 2025

Questions and answers

What is Alnylam Pharmaceuticals's net income?

Alnylam Pharmaceuticals reported a net income of $314M for the year ended Dec 31, 2025.

Numbers as reported in Alnylam Pharmaceuticals's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology